Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Amgen stock slouched Wednesday after an Eli ... He noted the fourth-quarter sales beat largely stemmed from Neulasta, Nplate and Prolia. Neulasta and Nplate help the body make white blood cells ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Wall Street analysts forecast that Amgen (AMGN) will report quarterly ... The consensus estimate for 'Product Sales- Neulasta- Total' stands at $121.89 million. The estimate indicates a year ...